NEW YORK (TheStreet) -- GW Pharmaceuticals
(GWPH) shares are up 3% to $64 on Monday following the announcement that its Sativex drug treatment had received a "fast track" designation from regulators at the Food and Drug Administration.
The fast track program is designed to facilitate the development of drugs intended to treat life threatening diseases.
Sativex, a cannaboid based treatments that is comprised of CBD (cannabidiol) and THC, is designed to treat pain associated with advanced stages of cancer. It is currently in Phase 3 clinical trials.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts